Abstracts tagged "autoimmune diseases"

Abstract Number: 1531 • ACR Convergence 2024
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Meggan Mackay¹, Catriona Wagner², Ashley Pinckney³, Jeffrey Cohen⁴, Zachary Wallace⁵, Arezou Khosroshahi⁶, Jeffrey Sparks⁷, Sandra Lord⁸, Amit Saxena⁹, Roberto Caricchio¹⁰, Alfred Kim¹¹, Diane Kamen¹², Fotios Koumpouras¹³, Anca Askanase¹⁴, Kenneth Smith¹⁵, Joel Guthridge¹⁵, Susan Macwana¹⁶, Sean McCarthy¹⁷, Matthew Sherman¹⁸, Sanaz Daneshfar Hamrah¹⁹, Maria Veri¹⁹, Kate York²⁰, Sarah Walker²¹, Sandeep Narpala²², Robin Carroll²², Bob Lin²², Leonid Serebryanny²², Adrian McDermott²³, William Barry²¹, Ellen Goldmuntz²⁴, James McNamara²⁵, Sara Tedeschi²⁶, Amit Bar-Or²⁷, Dinesh Khanna²⁸, ACV01 Clinical Study Team¹⁵ and Judith James¹⁵, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Rho, St Louis Park, NC, ⁴Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH, ⁵Massachusetts General Hospital, Newton, MA, ⁶Emory University, Atlanta, GA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁸Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Seattle, WA, ⁹NYU School of Medicine, New York, NY, ¹⁰University of Massachusetts Chan Medical School, Worcester, MA, ¹¹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹²Medical University of South Carolina, Charleston, SC, ¹³Yale School of Medicine, New Haven, CT, ¹⁴Columbia University Medical Center, New York, NY, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Oklahoma Medical Research Foundation, Oklahoma City, ¹⁷DAIT/NIAID/NIH, Rockville, MD, ¹⁸DAIT/NIAID/NIH, Washington, DC, ¹⁹Division of Allergy, Immunology, and Transplantation, NIH/NIAID, Bethesda, MD, USA., Bethesda, MD, ²⁰Rho Federal Systems Division, Durham, NC, USA., Durham, NC, ²¹Rho, Durham, NC, ²²Vaccine Research Center, NIH/NIAID, Bethesda, MD, USA, Bethesda, MD, ²³Vaccine Research Center, NIH/NIAID, Bethesda, MD, ²⁴NIAID/ NIH, Washington, DC, ²⁵NIH, Bethesda, MD, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, Philadelphia, PA, ²⁸Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…
Abstract Number: 1652 • ACR Convergence 2024
Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome
Lily BRUYERE¹, Anne-Claire DUCHEZ², Martin KILLIAN³ and Stéphane PAUL⁴, ¹université jean-monnet, saint-etienne, ²EFS, saint-etienne, ³chu Saint-Etienne, saint-etienne, ⁴CIRI, Saint Etienne, France
Background/Purpose: Extracellular Vesicles (EVs) are double lipid bilayer-enclosed membranous vesicles, produced and discharged from almost all cells. EVs are known for inter-cellular communication by releasing…
Abstract Number: 1784 • ACR Convergence 2024
T-bet Expressing B Cells as a Putative Prognostic and Therapeutic Biomarker for Human SLE
Athanasios Sachinidis¹, Maria Trachana², Anna Taparkou², George Gavriilidis³, Vasileios Vasileiou³, Sofoklis Keisaris³, Panayotis Verginis⁴, Christina Adamichou⁵, Dimitrios Boumpas⁶ and Alexandros Garyfallos², ¹School of Medicine, Aristotle University of Thessaloniki, Greece, Thessaloniki, Greece, ²Ippokrateio General Hospital Thessaloniki, Thessaloniki, Greece, ³Centre for Research and Technology Hellas, Thessaloniki, Greece, ⁴Medical School, University of Crete, Heraklion, Crete, Greece, ⁵IPPOKRATEION HOSPITAL OF THESSALONIKI, Athens, Greece, ⁶4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece, Athens, Greece
Background/Purpose: T-bet+ B cells, known as age-associated B cells (ABCs) and/or double-negative B cells (DN), expand in various autoimmune diseases. This study aimed to clarify…
Abstract Number: 1857 • ACR Convergence 2024
Thymic Mimetic Cells in Humans, Mice and Fish Are Evolutionarily Ancient with Species-specific Adaptations
Brooke Huisman¹, Daniel Michelson¹, Sara Rubin¹, Katherine Kohlsaat², Wilson Gomarga², Yuan Fang¹, Ji Myung Lee², Pedro del Nido², Meena Nathan², Christophe Benoist¹, Leonard Zon² and Diane Mathis¹, ¹Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Boston, MA
Background/Purpose: Thymic mimetic cells are molecular hybrids between medullary thymic epithelial cells (mTECs) and diverse peripheral cell types. They are involved in eliminating autoreactive T…
Abstract Number: 1982 • ACR Convergence 2024
Comparison of COVID-19 Infection and Mortality Rates in Vaccinated and Unvaccinated Patients with Autoimmune Inflammatory Rheumatic Disease (AIRD) Using Conventional and Biologic DMARD Therapy at an Urban Tertiary Care Hospital
Sarah Ifteqar¹, Mallak Zatreh², Aatif Syed¹, Xiangni Wu³, Asad Kabir⁴, John Foxworth⁵ and AMR EDREES⁶, ¹University of Missouri Kansas City, Kansas City, MO, ²3. Hutchinson Regional Medical Center, Hutchinson, Kansas, USA, Kansas City, ³UMKC, KANSAS CITY, MO, ⁴5. Pulmonary Critical Care, Mosaic Life Care Health System, St. Joseph, Missouri, USA, Kansas City, ⁵2. Department of Internal Medicine, University of Missouri Kansas City, Kansas City, Missouri, USA, Kansas City, ⁶UMKC, Overland Park, KS
Background/Purpose: Autoimmune inflammatory rheumatic diseases (AIRD) such as rheumatoid arthritis and systemic lupus erythematosus affect 3-5% of Americans and causes significant morbidity due to chronic…
Abstract Number: 2171 • ACR Convergence 2024
A Qualitative Exploration of Oral Healthcare Needs Amongst Canadian Patients with Rheumatic Diseases and Their Providers
Chrysi Stavropoulou¹, Corrie Billedeau², Jennifer Protudjer¹ and Carol Hitchon¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²NA, Winnipeg, MB, Canada
Background/Purpose: Patients with autoimmune rheumatic diseases (RDs) have a high prevalence of oral manifestations and/or oral side effects from immunomodulatory medications. These factors combined with…
Abstract Number: 2411 • ACR Convergence 2024
Attainment of Complete Renal Response in Patients with Active Lupus Nephritis: A Multi-Center Cohort Study
Arushi Ramnarain¹, Xiaomeng Xu², Joanna Kent³, Sagar Jagtiani⁴, Worawit Louthrenoo⁵, Laniyati Hamijoyo⁶, Shue-Fen Luo⁷, Yi-Hsing Chen⁸, Jiacai Cho⁹, Chiu Wai Shirley Chan¹⁰, Sandra Navarra¹¹, Haihong Yao¹², Lydia Pok¹³, BMDB Basnayake¹⁴, Zhuoli Zhang¹⁵, Madelynn Chan¹⁶, Sang-Cheol Bae¹⁷, Yasuhiro Katsumata¹⁸, Jun Kikuchi¹⁹, Sean O'Neill²⁰, Fiona Goldblatt²¹, Yih Jia Poh²², Mark Sapsford²³, Nicola Tugnet²⁴, Kristine Pek Ling Ng²⁵, Cherica Tee²⁶, Yoshiya Tanaka²⁷, Mandana Nikpour²⁸, Alberta Hoi²⁹, Eric Morand³⁰ and Rangi Kandane-Rathnayake³¹, ¹Monash Health, Melbourne, Victoria, Australia, ²GSK, Value, Evidence & Outcomes, Singapore, Singapore, ³Monash University, Department of Nephrology, Monash Health and Department of Medicine, Melbourne, Australia, ⁴Glaxo Smith Kline, Singapore, Singapore, ⁵Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, Chiang Mai, Thailand, ⁶Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ⁹National University Hospital, Singapore, Singapore, ¹⁰Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ¹¹University of Santo Tomas, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Department of Rheumatology and Immunology, Beijing, China, ¹³University of Malaya Medical Center, Department of Medicine, Faculty of Medicine,, Kuala Lumpur, Malaysia, ¹⁴Teaching Hospital, Kandy, Sri Lanka, ¹⁵Peking University First Hospital, Beijing, China, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁸Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁹Keio University School of Medicine, Tokyo, Japan, ²⁰Liverpool Hospital; Royal North Shore Hospital; University of New South Wales and the University of Sydney, Sydney, New South Wales, Australia, ²¹Flinders Medical Centre, Adelaide, Australia, ²²SingHealth, Singapore, Singapore, ²³WDHB, Auckland, New Zealand, ²⁴Auckland District Health Board, Auckland, New Zealand, ²⁵Health New Zealand, Auckland, New Zealand, ²⁶Department of Pediatrics, College of Medicine, University of the Philippines, Manila, Philippines, ²⁷Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁸The University of Sydney, Melbourne, Victoria, Australia, ²⁹Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ³⁰School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ³¹Monash University, Clayton, Victoria, Australia
Background/Purpose: LN is prevalent in SLE, occurring in up to 50% of patients. Treatment response is evaluated by improvement in proteinuria and renal function, and…
Abstract Number: 2549 • ACR Convergence 2024
VISTA Deficiency Alters the Skin Immune Cell Composition and Confers Skin Sensitivity to UV Light
Zachary Peters¹, Lindsay Mendyka², Angelique Cortez¹, J'voughnn Blake¹, Alecia Roy¹, William Rigby³, Christopher Burns⁴, Randolph Noelle⁵ and Sladjana Skopelja-Gardner⁶, ¹Dartmouth College, Lebanon, NH, ²Dartmouth Hitchcock Memorial Hospital, Lyme, NH, ³Dartmouth-Hitchcock, Norwich, VT, ⁴Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁵Geisel School of Medicine at Dartmouth, Lebanon, ⁶Dartmouth Geisel School of Medicine, Lebanon, NH
Background/Purpose: Persistent production of type I interferons (IFN-Is) is one of the hallmarks of cutaneous lupus erythematosus (CLE) that is exacerbated by ultraviolet (UV) light.…
Abstract Number: 2681 • ACR Convergence 2024
Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021
Ami Vyas, Steven Cohen and Christine Eisenhower, University of Rhode Island, Kingston, RI
Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 0095 • ACR Convergence 2024
Expansion of Brain T Cell Subsets Outside of the Choroid Plexus in Murine Models of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Minjung Kim¹, Cecilia Stumpf², Hadijat Makinde¹, Mohammad Khan¹, Vanessa Rodriguez², Tyler Therron², Jeremy Tilstra³, Deborah Winter⁴ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³University of Pittsburgh, Pittsburgh, PA, ⁴Northwestern University, Skokie, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (psychosis, anxiety disorder, cognitive dysfunction) may lead to the devastating impact of this disease on patients’ health-related quality-of-life, representing…
Abstract Number: 0255 • ACR Convergence 2024
“Rheum” to Improve: Have Patients Attending the Young Adult Systemic Erythematosus (YASLE) Clinic Received All Appropriate Vaccinations? A Quality Improvement Initiative
Razan Al Yaarubi¹, Amanda Steiman¹ and Earl Silverman², ¹University of Toronto, Toronto, ON, Canada, ²Silverman, Toronto, ON, Canada
Background/Purpose: Infections are a leading cause of morbidity and mortality in patients with childhood-onset systemic lupus erythematosus (cSLE). Vaccination is a powerful tool to prevent…
Abstract Number: 0318 • ACR Convergence 2024
The Relevance of a Positive ANA in New Patient Referrals to Rheumatology
Chi Chi Lau¹ and Ayesha Arif², ¹University of Vermont Medical Center, colchester, VT, ²University of Vermont Medical Center, Essex Junction, VT
Background/Purpose: A positive (+)ANA titer is a common reason for Rheumatology consultation, yet the ANA is a nonspecific, non-diagnostic, lab test that is positive in…
Abstract Number: 0532 • ACR Convergence 2024
An Immune-molecular Signature Specifically Modulated by JAK Inhibitors Ex Vivo May Serve as a Predictor of Therapy Response In Vivo to These Drugs
Sagrario Corrales¹, Carlos Perez-Sanchez¹, Laura Muñoz-Barrera¹, Rafaela Ortega-Castro², Elena Moreno-Caño³, Jerusalén Calvo⁴, Concepción Aranda-Valera³, María Lourdes Ladehesa-Pineda⁵, Pilar Font¹, Ismael Sánchez Pareja¹, María Carmen Ábalos-Aguilera⁶, Desiree Ruiz-Vilchez⁴, Christian Merlo⁷, Mª Angeles Aguirre-Zamorano⁸, Tomás Cerdó¹, Nuria Barbarroja¹, Marta Alarcon-Riquelme⁹, Alejandro Escudero-Contreras¹ and Chary Lopez-Pedrera⁵, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ²Hospital Reina Sofía, Cordoba, Andalucia, Spain, ³IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁷Rheumatology Service, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain, ⁸IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain, ⁹Fundación Progreso y Salud, Andalusian Government, Granada, Spain
Background/Purpose: Despite significant therapeutic advancements in rheumatoid arthritis (RA), a substantial proportion of patients (20-40%) remain unresponsive to current treatments, including targeted synthetic DMARDs. A…
Abstract Number: 0773 • ACR Convergence 2024
Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration
Leonie Middelink¹, Annemarie Kip², Maarten van der Linden³, Sangeeta Kumari², Stephanie van Dalen², Josephine Stein⁴, Tirza Bruurmijn², Martyn Foster⁵, Peter van Zandvoort², Patrick Round², Eric Meldrum², Helmuth van Es² and Renato Chirivi², ¹Citryll, Oss, Noord-Brabant, Netherlands, ²Citryll BV, Oss, Noord-Brabant, Netherlands, ³Citryll BV, Oss, Netherlands, ⁴Citryll BV, Oss, Noord-Holland, Netherlands, ⁵Experimental Pathology Consultancy, Benfleet, United Kingdom
Background/Purpose: Neutrophil extracellular traps (NETs) contribute to the pathophysiology of many immune-mediated inflammatory diseases (IMIDs). Though NETosis-targeting therapeutics have shown potential as effective treatments, currently…

« Previous Page
1
…
8
9
10
11
12
…
80
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.